Knowledge of hormone receptor and ERBB2 status as well as the global gene expression profiles of breast tumor samples may permit more accurate prognostic tests to be developed and would strengthen the value of the many breast tumor gene expression profiles in public depositories. This evidence concerns the gene NR4A1 and breast neoplasm.